Greece (GR)

Integral representations for the double-diffusivity system on the half-line (2024) Chatziafratis A, Aifantis EC, Carbery A, Fokas AS Journal article The Role of Urothelial Cancer-Associated 1 in Gynecological Cancers (2024) Nousiopoulou E, Vrettou K, Damaskos C, Garmpis N, Garmpi A, Tsikouras P, Nikolettos N, et al. Journal article, Review article Simultaneous Lightwave Information and Power Transfer in 6G Networks (2024) Papanikolaou V, Tegos SA, Palitharathna KW, Diamantoulakis PD, Suraweera HA, Khalighi MA, Karagiannidis GK Journal article The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects (2024) Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon Mv, Subklewe M, et al. Journal article Management of vesicoenteric fistulas arising from perforated Meckel’s diverticulum: a report of a case and review of the literature (2024) Diamantidis D, Papatheodorou N, Kostoglou P, Tsakaldimis G, Botaitis S Journal article The eROSITA upper limits: Description and access to the data (2024) Tubín-Arenas D, Krumpe M, Lamer G, Haase J, Sanders J, Brunner H, Homan D, et al. Journal article The legal and ethical framework governing body donation in Europe – 2nd update on current practice (2024) Brenner E, Bleys RL, de Caro R, Catereniuc I, Chirculescu AR, Destrieux C, Eppler E, et al. Journal article, Review article Multiword expressions, collocations and the OntoLex vocabulary (2024) Chiarcos C, Ionov M, Apostol ES, Gkirtzou K, Kabashi B, Khan AF, Truică CO Book chapter / Article in edited volumes Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression (2024) Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, et al. Journal article Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party (2024) Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Schetelig J, Eder M, Rösler W, et al. Journal article